Health Care - Spark Newswire

1 minute read

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

Today, 8:13 AM

The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose

PSTV

1 minute read

Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off

By Vandana Singh

Today, 6:47 AM

Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…

NVS

1 minute read

Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023

By Vandana Singh

Today, 6:34 AM

Edwards Lifesciences Corp (NYSE:EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61.…

5 minute read

Mesoblast Says Resumbits Biologic License Application To FDA For Remestemcel-L In Children With With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

By Michael Horton

Yesterday, 6:33 PM

Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with Enhanced Survival New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality

MESO

1 minute read

UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline

By Vandana Singh

Yesterday, 2:31 PM

UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

QURE

1 minute read

FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity

By Vandana Singh

Yesterday, 2:26 PM

William Blair has upgraded FibroGen Inc (NASDAQ:FGEN) from Market Perform To Outperform, citing a deep dive opportunity for its wholly owned monoclonal…

FGEN

1 minute read

Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts

By Vandana Singh

Yesterday, 2:15 PM

Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…

ALPMF

1 minute read

Why Are Hillstream BioPharma Shares Trading Over 100% Today?

By Vandana Singh

Yesterday, 11:41 AM

Hillstream BioPharma Inc (NASDAQ:HILS) signed an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. The MUC1 gene…

HILS